Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Mylan Inc.
Deal Size: $100.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement June 01, 2020
Mylan has decided to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA), the market-leading neuromodulator.